We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $269M
1-Year Est. Return 103.38%
This Fund
S&P 500
This Quarter Est. Return
+42.01%
1 Year Est. Return
+103.38%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$293M
AUM Growth
+$81.7M
Cap. Flow
+$12.9M
Cap. Flow %
4.42%
Top 10 Hldgs %
60.12%
Holding
48
New
11
Increased
16
Reduced
7
Closed
9

Top Buys

Rank Stock Value
1
EYPT icon
EyePoint Inc
EYPT
+$7.48M
2
GUTS icon
Fractyl Health
GUTS
+$6.49M
3
MDWD icon
MediWound
MDWD
+$6.31M
4
HELP
Cybin Inc
HELP
+$4.88M
5
ATYR
aTyr Pharma
ATYR
+$4.71M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$9.79M
2
URGN icon
UroGen Pharma
URGN
+$7.43M
3
REPL icon
Replimune Group
REPL
+$5.75M
4
PHVS icon
Pharvaris
PHVS
+$3.94M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$3.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.72%
2 Miscellaneous 3.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PYPD icon
26
PolyPid
PYPD
$103M
$3.06M 1.05%
918,668
-56,794
-6% -$197K
QQQ icon
27
PUT
Invesco QQQ Trust
QQQ
$489B
$1.56M 0.53%
+250,000
New +$143M
BFRI icon
28
Biofrontera
BFRI
$23.6M
$1.12M 0.38%
1,140,764
+164,316
+17% +$149K
ATXS
29
DELISTED
Astria Therapeutics
ATXS
$1.11M 0.38%
+152,853
New +$1.03M
XNTK icon
30
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
$951K 0.32%
2,128,300
+1,578,300
+287% +$389M
TRVI icon
31
Trevi Therapeutics
TRVI
$2.39B
$915K 0.31%
100,000
-200,000
-67% -$1.5M
VSTM icon
32
CALL
Verastem
VSTM
$654M
$898K 0.31%
+646,500
New +$4.81M
KURA icon
33
Kura Oncology
KURA
$1.13B
$885K 0.3%
100,000
– –
SPY icon
34
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$718K 0.25%
300,000
+50,000
+20% +$32.1M
RZLT icon
35
CALL
Rezolute
RZLT
$445M
$546K 0.19%
+263,100
New +$1.75M
IDYA icon
36
CALL
IDEAYA Biosciences
IDYA
$3.87B
$237K 0.08%
35,900
+15,900
+80% +$385K
REPL icon
37
CALL
Replimune Group
REPL
$1.46B
$183K 0.06%
511,400
+279,600
+121% +$1.79M
OEF icon
38
PUT
iShares S&P 100 ETF
OEF
$20.5B
$20K 0.01%
+200,000
New +$63.6M
SRRK icon
39
PUT
Scholar Rock
SRRK
$7.04B
$10K ﹤0.01%
+100,000
New +$3.5M
CMPS
40
Compass Pathways
CMPS
$1.9B
– –
-482,651
Closed -$1.35M
CRNX icon
41
CALL
Crinetics Pharmaceuticals
CRNX
$9B
– –
-52,700
Closed -$58K
INMB icon
42
PUT
INmune Bio
INMB
$64.7M
– –
-1,033,200
Closed -$1.76M
KALV
43
DELISTED
KalVista Pharmaceuticals
KALV
– –
-157,725
Closed -$1.78M
OVID icon
44
Ovid Therapeutics
OVID
$547M
– –
-500,000
Closed -$165K
PHVS icon
45
Pharvaris
PHVS
$2.48B
– –
-223,627
Closed -$3.94M
REPL icon
46
Replimune Group
REPL
$1.46B
– –
-900,000
Closed -$5.75M
URGN icon
47
CALL
UroGen Pharma
URGN
$2.13B
– –
-100,000
Closed -$600K
URGN icon
48
UroGen Pharma
URGN
$2.13B
– –
-542,366
Closed -$7.43M
1
2

Similar funds

GPFA
Game Plan Financial Advisors Westlake, Ohio $269M AUM 28.74% 1-Year Est. Return
AFO
Allie Family Office Miami, Florida $269M AUM 20.2% 1-Year Est. Return
TW
Titan Wealth St Peter Port $269M AUM
PM
Plustick Management Charlottesville, Virginia $269M AUM 340.55% 1-Year Est. Return
ZEP
Zeno Equity Partners London, United Kingdom $269M AUM 6.35% 1-Year Est. Return
LBW
Landesbank Baden-Wuerttemberg Stuttgart Baden-Wuerttemberg, Germany $269M AUM
VP
Verisail Partners Chamblee, Georgia $270M AUM 16.03% 1-Year Est. Return
5W
5T Wealth Napa, California $269M AUM 17.81% 1-Year Est. Return

Rosalind Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Rosalind Advisors held 48 positions worth $293M, up 39% from $211M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Rosalind Advisors deployed $12.9M of net new capital in Q3 2025, opening 11 new positions and adding to 16 existing holdings. Its largest new stake was EyePoint Inc: 650,000 shares worth $9.26M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $9.79M trimmed.

  • Rosalind Advisors's largest Q3 2025 buy was EyePoint Inc: 650,000 shares worth $9.26M.
  • Rosalind Advisors added most to MediWound in Q3 2025, an estimated $6.31M increase.
  • Rosalind Advisors's biggest Q3 2025 reduction was Ocular Therapeutix, cutting an estimated $9.79M.
  • Rosalind Advisors fully exited UroGen Pharma in Q3 2025, selling an estimated $7.43M.
  • Rosalind Advisors's ten largest holdings make up 60% of its $293M portfolio in Q3 2025.
  • Rosalind Advisors opened 11 new positions and closed 9 in Q3 2025.
  • Rosalind Advisors's portfolio value rose 39% quarter-over-quarter to $293M.

Based on Rosalind Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.